· Regulation · Regulation Desk
A Hague court ordered Ceban to halt sales on August 5, 2026, rejecting a pharmacy exemption defence. The ruling extends Novo Nordisk's enforcement campaign into Europe and targets non-injection dosage-form workarounds.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.